Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR | P43088 | 16/20 | 1.00 |
| ▸ | PTGER3 | P43115 | 5/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.81 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.81 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.78 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.78 |
| ▸ | THRB | P10828 | 1/20 | 0.78 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluprostenol SCHEMBL16414486 | 1.00 | PTGFR (1.00) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| Fluprostenol SCHEMBL16414497 | 1.00 | PTGFR (1.00) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| Fluprostenol SCHEMBL2744986 | 1.00 | PTGFR (1.00) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| Fluprostenol SCHEMBL10015915 | 1.00 | PTGFR (1.00) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| Fluprostenol SCHEMBL24342036 | 1.00 | PTGFR (1.00) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| Fluprostenol SCHEMBL13260302 | 1.00 | PTGFR (1.00) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| Fluprostenol SCHEMBL24342073 | 1.00 | PTGFR (1.00) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| Fluprostenol SCHEMBL6750653 | 1.00 | PTGFR (1.00) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| Fluprostenol SCHEMBL230607 | 1.00 | PTGFR (1.00) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| Fluprostenol SCHEMBL20860290 | 1.00 | PTGFR (1.00) | PTGFRPTGER3ABCC4ABCB11TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105771-A1 | AMINO ACID SALTS OF PROSTAGLANDINS | NOVAER HOLDINGS, INC. | 2010-04-29 | — | — | US | claimed |
| US-20250074935-A1 | HETERODIMER COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | RIPPLE THERAPEUTICS CORPORATION (CA) | 2025-03-06 | — | — | US | disclosed |
| US-20250057962-A1 | PROCESSABLE COMPOSITIONS AND USE FOR THE SAME | RIPPLE THERAPEUTICS CORPORATION (CA) | 2025-02-20 | — | — | US | disclosed |
| WO-2023079362-A1 | PROCESSABLE COMPOSITIONS AND USE FOR THE SAME | RIPPLE THERAPEUTICS CORPORATION (CA) | 2023-05-11 | — | — | WO | disclosed |
| US-11279729-B2 | Heterodimer compositions and methods for the treatment of ocular disorders | RIPPLE THERAPEUTICS CORPORATION (CA) | 2022-03-22 | — | — | US | disclosed |
| US-20210347809-A1 | HETERODIMER COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | RIPPLE THERAPEUTICS CORPORATION (CA) | 2021-11-11 | — | — | US | disclosed |
| US-10822321-B2 | Processes and intermediates for the preparations of isomer free prostaglandins | CHIROGATE INTERNATIONAL INC. (TW) | 2020-11-03 | — | — | US | disclosed |
| US-10280138-B2 | Nitric oxide donating derivatives of fluprostenol | NICOX S.A. (FR) | 2019-05-07 | — | — | US | disclosed |
| EP-2349242-B1 | AMINO ACID SALTS OF PROSTAGLANDINS | NOVAER HOLDINGS INC (US) | 2018-12-05 | — | — | EP | disclosed |
| US-20180251442-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF ISOMER FREE PROSTAGLANDINS | CHIROGATE INTERNATIONAL INC. (TW) | 2018-09-06 | — | — | US | disclosed |
| US-20150336921-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF ISOMER FREE PROSTAGLANDINS | CHIROGATE INTERNATIONAL INC. (TW) | 2015-11-26 | — | — | US | disclosed |
| US-20150336923-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF ISOMER FREE PROSTAGLANDINS | CHIROGATE INTERNATIONAL INC. (TW) | 2015-11-26 | — | — | US | disclosed |
| US-9115109-B2 | Processes and intermediates for the preparations of isomer free prostaglandins | CHIROGATE INTERNATIONAL INC. (TW) | 2015-08-25 | — | — | US | disclosed |
| US-20150051410-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF ISOMER FREE PROSTAGLANDINS | CHIROGATE INTERNATIONAL INC. (TW) | 2015-02-19 | — | — | US | disclosed |
| US-8722739-B2 | Amino acid salts of prostaglandins | NOVAER HOLDINGS, INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-8623918-B2 | Amino acid salts of prostaglandins | NOVAER HOLDINGS, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8470882-B2 | — | — | 2013-06-25 | — | — | US | disclosed |
| US-20130131106-A1 | BIFUNCTIONAL RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | INSPIRE PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20100105771-A1 | AMINO ACID SALTS OF PROSTAGLANDINS | NOVAER HOLDINGS, INC. | 2010-04-29 | — | — | US | disclosed |
| US-20100105775-A1 | AMINO ACID SALTS OF PROSTAGLANDINS | NOVAER HOLDINGS, INC. | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074935-A1 | HETERODIMER COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | CRYAB, UACA, CRYAA | PTGFR 7/4885PTGER3 22/4885ABCC4 4002/4885 |
| US-20250057962-A1 | PROCESSABLE COMPOSITIONS AND USE FOR THE SAME | CCND2, CCND1, C9 | PTGFR 128/4885PTGER3 323/4885ABCC4 2746/4885 |
| US-20180251442-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF ISOMER FREE PROSTAGLANDINS | PTGER2, PTGES2, PTGER1 | PTGFR 16/4885PTGER3 11/4885ABCC4 2336/4885 |
| US-20100105771-A1 | AMINO ACID SALTS OF PROSTAGLANDINS | PTGIS, PTGES, PTGIR | PTGFR 7/4885PTGER3 16/4885ABCC4 4544/4885 |
| US-20100105775-A1 | AMINO ACID SALTS OF PROSTAGLANDINS | PTGIS, PTGES, PTGIR | PTGFR 7/4885PTGER3 16/4885ABCC4 4544/4885 |
| US-11279729-B2 | Heterodimer compositions and methods for the treatment of ocular disorders | CRYAB, UACA, CRYAA | PTGFR 7/4885PTGER3 22/4885ABCC4 4002/4885 |
| US-20150336923-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF ISOMER FREE PROSTAGLANDINS | PTGER2, PTGES2, PTGER1 | PTGFR 16/4885PTGER3 11/4885ABCC4 2336/4885 |
| US-10280138-B2 | Nitric oxide donating derivatives of fluprostenol | PTGIS, NOS2, PTGIR | PTGFR 21/4885PTGER3 23/4885ABCC4 2484/4885 |
| US-10822321-B2 | Processes and intermediates for the preparations of isomer free prostaglandins | PTGER2, PTGES2, PTGER1 | PTGFR 16/4885PTGER3 11/4885ABCC4 2336/4885 |
| US-20150336921-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF ISOMER FREE PROSTAGLANDINS | PTGER2, PTGES2, PTGER1 | PTGFR 16/4885PTGER3 11/4885ABCC4 2336/4885 |
| US-20210347809-A1 | HETERODIMER COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | CRYAB, UACA, CRYAA | PTGFR 7/4885PTGER3 22/4885ABCC4 4002/4885 |
| US-20150051410-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF ISOMER FREE PROSTAGLANDINS | PTGER2, PTGES2, PTGER1 | PTGFR 16/4885PTGER3 11/4885ABCC4 2336/4885 |
| US-20130131106-A1 | BIFUNCTIONAL RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | ROCK2, ROCK1, RHOA | PTGFR 762/4885PTGER3 1513/4885ABCC4 4340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.